• Join
  • Login
  • Contact
Press Releases 

FIP adds biosimilars to policy on pharmacists’ right to substitute one medicine for another

All press releases

The Hague • 2 October 2018

Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, the International Pharmaceutical Federation (FIP) made clear today. The federation has published a revised Statement of Policy on “Pharmacists’ authority in pharmaceutical product selection: Therapeutic interchange and substitution”, which has been updated to account for the emergence of biological medicines and their biosimilars onto the medical landscape. 

The core principles that were in the original statement remain, and include: that generic substitution is recommended as part of the pharmacist’s dispensing role; that pharmacists should be provided with bioavailability data by regulatory authorities and manufacturers; and that a medicine should only be substituted with a product containing a different active ingredient in agreement with the prescriber. The use of generic names is still encouraged, but the revised statement gives focus to the use of international non-proprietary names in particular. The revision also recommends that, to ensure safety, information about excipients should be taken into account when making decisions on substitution.

“To date, no major safety issues with the use of biosimilars as alternatives to the original biological medicine have been reported,” the statement says. However, the new text calls for “adequate pharmacovigilance” to ensure identification of a biological medicine should any product-specific safety (or immunogenicity) concerns arise, as well as for post-marketing safety studies by companies marketing generic medicines or biosimilars, with safety updates to be made publicly accessible.

“Pharmacists are key stakeholders in product selection and evaluation. The purpose of this policy is to guarantee quality and good pharmacy practice in this area of pharmacists’ activities. FIP supports well regulated processes in product changes where goals of safety, positive patient outcomes and economic benefits can be achieved with a good collaboration of all parties,” said FIP Vice President Eeva Teräsalmi.


Notes for editors

Links: The full FIP Statement of Policy “Pharmacist’s authority in pharmaceutical product selection: Therapeutic interchange and substitution” can be found here

The International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists, and is in official relations with the World Health Organization. Through its 144 member organisations, it represents over four million practitioners and scientists around the world.

Lin-Nam Wang, communications manager
Tel +31 6 316 29160

Last update 5 July 2018

FIP Congresses